precision
biosciences
report
third
quarter
financial
results
november
durham
globe
newswire
precision
biosciences
nasdaq
dtil
biotechnology
company
dedicated
improving
life
novel
proprietary
genome
editing
platform
today
announced
publish
financial
results
third
quarter
provide
business
update
tuesday
november
precision
biosciences
inc
precision
biosciences
clinical
stage
biotechnology
company
dedicated
improving
life
dtil
novel
proprietary
genome
editing
platform
arcus
highly
specific
versatile
genome
editing
platform
designed
therapeutic
safety
delivery
control
mind
using
arcus
company
pipeline
consists
multiple
car
immunotherapy
clinical
candidates
several
vivo
gene
correction
therapy
candidates
cure
genetic
infectious
diseases
adequate
treatments
exist
information
precision
biosciences
please
visit
investor
contact
alex
kelly
chief
corporate
affairs
officer
